Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)
|
6 Months Ended |
Sep. 30, 2021 |
|---|
| Share-based Payment Arrangement [Abstract] |
|
| Schedule of stock based compensation expenses |
| |
|
Three months ended
September 30, |
|
|
Six months ended
September 30, |
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| |
|
(Unaudited) |
|
|
(Unaudited) |
|
|
(Unaudited) |
|
|
(Unaudited) |
|
| Research and development expenses |
|
$ |
113 |
|
|
$ |
141 |
|
|
$ |
145 |
|
|
$ |
1,293 |
|
| Selling, general and administrative expenses |
|
|
2,988 |
|
|
|
830 |
|
|
|
5,539 |
|
|
|
7,757 |
|
| Total stock-based compensation |
|
$ |
3,101 |
|
|
$ |
971 |
|
|
$ |
5,684 |
|
|
$ |
9,050 |
|
|
| Schedule of restricted stock awards |
| |
|
Number of
Shares |
|
|
Weighted
Average
Grant-Date
Fair Value |
|
| Unvested at March 31, 2021 |
|
|
1,061,905 |
|
|
$ |
4.50 |
|
| Granted |
|
|
1,200,000 |
|
|
$ |
4.74 |
|
| Vested |
|
|
(222,222 |
) |
|
$ |
4.78 |
|
| Unvested at September 30, 2021 (unaudited) |
|
|
2,039,683 |
|
|
$ |
4.61 |
|
| |
|
Number of Shares |
|
|
Weighted Average Grant-Date Fair Value |
|
| Unvested at March 31, 2021 |
|
|
777,778 |
|
|
$ |
5.12 |
|
| Vested |
|
|
(66,666 |
) |
|
$ |
5.12 |
|
| Canceled |
|
|
(711,112 |
) |
|
$ |
5.12 |
|
| Unvested at September 30, 2021 (unaudited) |
|
|
- |
|
|
$ |
5.12 |
|
|
| Schedule of stock options granted |
| |
|
Three Months Ended
September 30, |
|
|
Six Months Ended
September 30, |
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Dividend yield |
|
|
0% |
|
|
|
0% |
|
|
|
0% |
|
|
|
0% |
|
| Expected price volatility |
|
|
50% |
|
|
|
50% |
|
|
|
50% |
|
|
|
50% |
|
| Risk free interest rate |
|
|
0.66%-1.30% |
|
|
|
0.16% - 0.44% |
|
|
|
0.35%-1.30% |
|
|
|
0.16% - 0.44% |
|
| Expected term |
|
|
5-7 years |
|
|
|
5-6 years |
|
|
|
3-7 years |
|
|
|
5-6 years |
|
|
| Schedule of stock options activity |
| |
|
Shares
Underlying
Options |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average Remaining
Contractual
Term
(Years) |
|
|
Aggregate
Intrinsic
Value |
|
| Outstanding at March 31, 2019 |
|
|
1,937,833 |
|
|
$ |
0.54 |
|
|
|
9.2 |
|
|
$ |
3,720,395 |
|
| Outstanding at March 31, 2020 |
|
|
1,937,833 |
|
|
$ |
0.54 |
|
|
|
8.2 |
|
|
$ |
4,243,610 |
|
| Granted |
|
|
8,949,107 |
|
|
$ |
3.23 |
|
|
|
8.4 |
|
|
|
|
|
| Exercised |
|
|
(25,000 |
) |
|
$ |
0.15 |
|
|
|
- |
|
|
|
|
|
| Outstanding at March 31, 2021 |
|
|
10,928,607 |
* |
|
$ |
2.73 |
|
|
|
8.2 |
|
|
$ |
17,524 |
|
| Granted |
|
|
1,227,204 |
|
|
$ |
3.49 |
|
|
|
9.8 |
|
|
|
|
|
| Exercised |
|
|
(419,000 |
) |
|
$ |
0.51 |
|
|
|
- |
|
|
|
|
|
| Canceled |
|
|
(816,379 |
) |
|
$ |
3.88 |
|
|
|
- |
|
|
|
|
|
| Outstanding at September 30, 2021 (unaudited) |
|
|
10,920,432 |
|
|
$ |
2.83 |
|
|
|
7.8 |
|
|
$ |
13,089 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at September 30, 2021 (unaudited) |
|
|
9,756,406 |
|
|
$ |
2.73 |
|
|
|
7.7 |
|
|
$ |
12,483 |
|
|
| Schedule of warrant activity |
| |
|
Shares
Underlying
Warrants |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average Remaining
Contractual
Term
(Years) |
|
|
Aggregate
Intrinsic
Value |
|
| Outstanding at March 31, 2021 |
|
|
3,883,083 |
|
|
$ |
2.49 |
|
|
|
4.6 |
|
|
$ |
7,763 |
|
| Issued |
|
|
550,724 |
|
|
$ |
4.07 |
|
|
|
5.0 |
|
|
|
|
|
| Canceled |
|
|
(133,630 |
) |
|
$ |
5.63 |
|
|
|
- |
|
|
|
|
|
| Outstanding at September 30, 2021 (unaudited) |
|
|
4,300,177 |
|
|
$ |
2.60 |
|
|
|
4.2 |
|
|
$ |
7,026 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at September 30, 2021 (unaudited) |
|
|
3,368,422 |
|
|
$ |
1.91 |
|
|
|
4.1 |
|
|
$ |
6,447 |
|
|
| Schedule of estimated the fair value of the warrants |
| |
|
Three Months Ended September 30, |
|
|
Six Months Ended September 30, |
|
| |
|
2021 |
|
|
2021 |
|
| Dividend yield |
|
|
0% |
|
|
|
0% |
|
| Expected price volatility |
|
|
50% |
|
|
|
50% |
|
| Risk free interest rate |
|
|
0.66%-1.30% |
|
|
|
0.35%-1.30% |
|
| Expected term |
|
|
5-7 years |
|
|
|
3-7 years |
|
|